Siemens has completed its acquisition of Dotmatics, a move that enhances Siemens’ standing in AI-powered PLM software and extends its reach into the Life Sciences sector. This strategic acquisition allows Siemens to leverage Dotmatics’ Scientific Intelligence Platform, Luma, along with its scientific applications, to enable AI-driven drug development and foster collaboration across the research-to-production value chain.
Roland Busch, President and CEO of Siemens AG, commented on the acquisition: “With Dotmatics, we’re building a new era of innovation in Life Sciences. From research through to production – we’re creating a unique, end-to-end digital thread: We combine Dotmatics’ scientific intelligence with our industrial AI technologies and digital twins.” He emphasized that this integration would help customers accelerate breakthroughs and reduce development cycles for pharmaceuticals.
The transaction is expected to expand Siemens’ total addressable market for industrial software by $11 billion. It aligns with Siemens’ ‘ONE Tech Company’ strategy aimed at driving innovation across industries. Dotmatics is projected to generate over $300 million in revenue for fiscal year 2025 with an adjusted EBITDA margin exceeding 40%, contributing positively to Siemens’ growth metrics.
Additionally, Siemens anticipates significant revenue synergies from this acquisition. Medium-term synergies are expected to be around $100 million annually, increasing to over $500 million per year in the long term.
